Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Avecho Biotechnology Limited ( (AU:AVE) ) is now available.
Avecho Biotechnology reported solid progress in its pivotal Phase III trial of its CBD TPM® soft-gel capsule for insomnia, with 190 of the roughly 210 patients required for the interim analysis already dosed and remaining recruitment continuing into early 2026. The company is targeting completion of this interim analysis in the first half of 2026, positioning the read-out as a key clinical and commercial inflection point that could significantly shape its path to market and value for shareholders. To accelerate its route to commercialisation, Avecho raised $2.5 million in a placement completed in November 2025, funding critical commercial-scale manufacturing, stability and regulatory batch work, and capsule production for the second Phase III cohort, with the goal of enabling a prompt TGA submission and preparing supply for Australia and potential licensed territories. The company also strengthened its intellectual property position after the US and European patent offices allowed patents covering its CBD TPM® soft-gel formulation, extending protection over its oral cannabinoid technology to at least 2040 in two of the world’s largest pharmaceutical markets, and supporting possible non-core opportunities beyond CBD. Avecho ended the December quarter with $4.7 million in cash and continued to invest heavily in R&D, particularly the Phase III insomnia trial and related manufacturing and regulatory activities, while noting that quarterly costs were elevated by timing effects and are not expected to remain at the same level.
The most recent analyst rating on (AU:AVE) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avecho Biotechnology Limited stock, see the AU:AVE Stock Forecast page.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian pharmaceutical biotechnology company focused on developing cannabinoid-based therapies utilising its proprietary Tocopheryl Phosphate Mixture (TPM®) delivery technology. Its lead product is a CBD TPM® soft-gel capsule targeting the treatment of insomnia, with an eye to regulatory approval and commercialisation in Australia and expansion into major international markets such as the United States and Europe.
Average Trading Volume: 6,893,507
Technical Sentiment Signal: Sell
Current Market Cap: A$36.73M
Learn more about AVE stock on TipRanks’ Stock Analysis page.